Patent application number | Description | Published |
20100096329 | Method of Removing Protein-Bound Deleterious Substances During Extracorporeal Renal Replacement Treatment - The invention is directed to a method of removing a deleterious substance bound to a protein in blood of a patient by introducing a displacer substance into the blood under conditions in which the displacer substance replaces deleterious substance bound to the protein, thereby resulting in additional unbound deleterious substance in the blood, and removing unbound deleterious substance from the blood by extracorporeal renal replacement treatment. | 04-22-2010 |
20100096330 | Method of Determining A Phosphorus Binder Dosage for a Dialysis Patient - The invention is directed to a method of determining a dosage of phosphorus binder for a patient undergoing dialysis treatment to achieve a pre-dialysis serum phosphorus concentration within a desired concentration range while achieving a desired net accumulation of calcium. The method includes determining the dosage of phosphorus binder that will achieve pre-dialysis serum phosphorus concentration of the patient that is within the desired concentration range while accounting for the change in the amount of phosphorus removed by the dialysis treatment when the pre-dialysis serum phosphorus concentration of the patient is within the desired concentration range, determining a dialysate calcium concentration that will result in the desired net accumulation of calcium over a complete dialysis cycle, and dialyzing the patient with a dialysate containing a calcium concentration based upon that determination. | 04-22-2010 |
20100099958 | Method of identifying when a patient undergoing hemodialysis is at increased risk of death - The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's systolic blood pressure, serum albumin level, body weight, and body temperature at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a substantial change in the rate of decline of at least one of the patient's systolic blood pressure, serum albumin level, body weight, and body temperature. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data in deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a substantial change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients. | 04-22-2010 |
20110079558 | METHOD OF CONTROLLING DIFFUSIVE SODIUM TRANSPORT IN DIALYSIS - A method of controlling diffusive sodium transport from the dialysate solution to the blood of a patient undergoing hemodialysis treatment or from the blood to the dialysate solution includes calculating SNa | 04-07-2011 |
20110137136 | METHOD OF IDENTIFYING WHEN A PATIENT UNDERGOING HEMODIALYSIS IS AT INCREASED RISK OF DEATH - The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, including systolic blood pressure, serum albumin concentration level, body weight, body temperature, serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients. | 06-09-2011 |
20110237996 | Methods of Regional Citrate Anticoagulation Dialysis - A method of performing regional citrate anticoagulant dialysis of a patient's blood includes flowing blood from and back to the patient through an extracorporeal circuit including a dialyzer having semi-permeable dialysis membranes and a dialysate chamber surrounding the membranes. The method further includes flowing a dialysate containing calcium and citrate through the dialysate chamber of the dialyzer and introducing citrate into the patient's blood upstream of the dialyzer, whereby the patient's blood is dialyzed. The method can further include predicting the concentration of systemic ionized calcium in the blood of the patient at any point in the dialysis treatment or post-dialysis, such as by a mathematical model. The method can further include statistically correcting the preliminary predicted post-dialysis concentration of systemic ionized calcium in the patient's blood to provide a final predicted post-dialysis systemic ionized calcium concentration. The method can further include statistically correcting the preliminary predicted systemic ionized calcium concentration for any time point during the dialysis treatment to provide a final predicted systemic ionized calcium concentration for that time point. | 09-29-2011 |
20110275922 | BIOIMPEDANCE METHODS AND APPARATUS - Methods and apparatus for providing bioimpedance analysis are provided. In certain aspects, equivalent circuit frequency response models are provided which lead to improved correlations with MRI data. The frequency response models take account of body composition, including the fat component of a body segment. Data obtained by performing bioimpedance spectroscopy (BIS) and MRI on the calves of subjects illustrates the improved correlations achieved compared to single frequency analyses at 50 kilohertz and analyses performed using the conventional Cole-Cole model. | 11-10-2011 |
20120253022 | METHOD OF REMOVING PROTEIN-BOUND DELETERIOUS SUBSTANCES DURING EXTRACORPOREAL RENAL REPLACEMENT TREATMENT - The invention is directed to a method of removing a deleterious substance bound to a protein in blood of a patient by introducing a displacer substance into the blood under conditions in which the displacer substance replaces deleterious substance bound to the protein, thereby resulting in additional unbound deleterious substance in the blood, and removing unbound deleterious substance from the blood by extracorporeal renal replacement treatment. | 10-04-2012 |
20130041684 | System And Method Of Identifying When A Patient Undergoing Hemodialysis Is At Increased Risk Of Death By A Logistic Regression Model - Identifying a patient undergoing periodic hemodialysis treatments at increased risk of death by a logistic regression model includes selecting one or more clinical or biochemical parameter parameters associated with a probability of death of the patient while the patient is undergoing periodic hemodialysis treatments, and estimating the probability of death of the patient over a future time interval by a logistic regression model including model coefficients, the model coefficients determined by analyzing data from deceased patients that were previously undergoing periodic hemodialysis treatments, the analysis including a longitudinal analysis backwards in time on the one or more clinical or biochemical parameters of the deceased patients. The patient is identified as having an increased risk of death if the probability of death of the patient is greater than a predetermined threshold probability. | 02-14-2013 |
20130197389 | DRY WEIGHT PREDICTOR - Methods and apparatus for predicting/estimating the dry weight of an individual, e.g., a patient undergoing dialysis treatment, are provided. The techniques employ a bioimpedance measurement ( | 08-01-2013 |
20130244263 | METHOD OF IDENTIFYING WHEN A PATIENT UNDERGOING HEMODIALYSIS IS AT INCREASED RISK OF DEATH - The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, consisting of serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's clinical or biochemical parameters. The invention is also directed to a method of identifying an increased mortality risk factor for a patient undergoing periodic hemodialysis treatment. The method includes analyzing data of deceased patients that were previously undergoing periodic hemodialysis treatments by performing a longitudinal analysis backwards in time of changes in a clinical or biochemical parameter the patients, and identifying a significant change in the rate of decline or the rate of increase in a clinical or biochemical parameter before death of the patients. | 09-19-2013 |
20140128791 | System and Method of Modeling Erythropoiesis Including Iron Homeostasis - A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, the model including iron homeostasis, and employing the patient parameters and an initially selected ESA administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen. The method then includes administering ESA to the patient with an ESA administration regimen predicted to adjust the patient's hematocrit and/or hemoglobin concentration to the desired range at the predetermined time. The method can be implemented in a hemodialysis system. | 05-08-2014 |
20140200181 | SYSTEM AND METHOD OF MODELING ERYTHROPOIESIS AND ITS MANAGEMENT - A method of adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a value within a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen includes obtaining patient parameters required for input into a model for predicting the patient's hematocrit and/or hemoglobin concentration at a predetermined time with a selected ESA administration regimen, and employing the patient parameters and an initially selected EPO administration regimen in the model to predict the patient's hematocrit and/or hemoglobin concentration at the predetermined time with the initially selected ESA administration regimen. Optionally, if the patient's hematocrit and/or hemoglobin concentration is not predicted by the model to be in the desired range at the predetermined time, the method includes employing the model with one or more different ESA administration regimens until the model predicts that the patient's hematocrit and/or hemoglobin concentration will be in the desired range at the predetermined time. The method then includes administering ESA to the patient with an ESA administration regimen predicted to adjust the patient's hematocrit and/or hemoglobin concentration to the desired range at the predetermined time. The method can be implemented in a computer system for adjusting a patient's undesired hematocrit and/or hemoglobin concentration to a desired range at a predetermined time with an erythropoiesis stimulating agent (ESA) regimen. | 07-17-2014 |
20140249384 | ESTIMATION OF THE DRY WEIGHT OF A DIALYSIS PATIENT - In an embodiment, the invention relates to methods, apparatus, computer programs and computer program products for estimating a dry weight of a dialysis patient comprising the steps of determining a first fluid status of the patient between treatment sessions in a first stage, determining a second fluid status of the patient during treatment sessions in a second stage and estimating the dry weight based on the second fluid status. | 09-04-2014 |
20140353251 | Methods of Regional Citrate Anticoagulation Dialysis - A method of performing regional citrate anticoagulant dialysis of a patient's blood includes flowing blood from and back to the patient through an extracorporeal circuit including a dialyzer having semi-permeable dialysis membranes and a dialysate chamber surrounding the membranes. The method further includes flowing a dialysate containing calcium and citrate through the dialysate chamber of the dialyzer and introducing citrate into the patient's blood upstream of the dialyzer, whereby the patient's blood is dialyzed. The method can further include predicting the concentration of systemic ionized calcium in the blood of the patient at any point in the dialysis treatment or post-dialysis, such as by a mathematical model. The method can further include statistically correcting the preliminary predicted post-dialysis concentration of systemic ionized calcium in the patient's blood to provide a final predicted post-dialysis systemic ionized calcium concentration. The method can further include statistically correcting the preliminary predicted systemic ionized calcium concentration for any time point during the dialysis treatment to provide a final predicted systemic ionized calcium concentration for that time point. | 12-04-2014 |
Patent application number | Description | Published |
20110289783 | APPARATUS AND METHOD FOR PROVIDING A HAND-HELD INSTRUMENT WITH AT LEAST ONE SELECTIVELY OPERABLE RETRACTABLE PROTECTIVE ELEMENT - The present invention is directed to a hand-held instrument, which may comprise, in various exemplary embodiments thereof, a folding (manual, assisted opening, automatic, etc,) knife, a fixed blade knife, or any other hand-held tool comprising a handle, and at least one active region (e.g., a cutting, a saw blade, etc.), and which also advantageously comprises at least one novel user-operable protective element, that when placed, by the user, into an active position that is generally perpendicular to the handle of the instrument, is configured for protecting at least a portion of the user's hand while the instrument is held and/or utilized, and that when placed into a retracted position that is generally parallel to the handle of the instrument, streamlines the instruments longitudinal profile. In accordance with the present invention, the inventive apparatus is advantageously provided with at least one actuating element selectively operable by the user, that when activated, causes a corresponding at least one protective element to automatically extend into the active position. In an alternate embodiment of the present invention, in which the novel instrument comprises an automatic opening blade that exists a predefined region within the handle thereof in response to the user's activation of an opening element, the novel instrument is advantageously provided with an actuating mechanism connected to at least one protective element that is operable to automatically cause the at least one protective element to extend into its active position in conjunction with the blade's automatic opening movement. | 12-01-2011 |